Tests disitamab vedotin with cisplatin before surgery for cervical cancer
Tests disitamab vedotin plus cisplatin before surgery in women with HER2-positive locally advanced cervical cancer.
Plain-language title generated from the registry record
Registry title: Neoadjuvant Therapy in Cervical Cancer
Key facts
- Where
- Jinan, ChinaSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for women aged 18 to 70 with cervical squamous cell cancer that is HER-2 positive. It tests Disitamab Vedotin with Cisplatin given before surgery.
- Age
- 18 to 70 years
- Sex
- Women only
- Disease stage
- Cervical squamous cell carcinoma. The summary mentions locally advanced disease, stages IB3 and IIA2.
- Biomarker or test result
- HER-2 positive
Main reasons for not taking part
- Cervical adenocarcinoma
Read by machine on 9 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT06558682, who can take part
Where in China
- Qilu Hospital of Shandong UniversityJinan, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Qilu Hospital of Shandong University
- Trial code
- NCT06558682
- Record updated
- 1 April 2025
- Original description
In the comprehensive dataset of clinical diagnoses and treatments for cervical cancer in China, 49.8% of patients with stage IB3 and IIA2 receive surgical intervention following neoadjuvant chemotherapy. This indicates a pressing need to optimize neoadjuvant chemotherapy regimens for locally advanced cervical cancer. While paclitaxel combined with cisplatin is the conventional approach, 9.8% to 30.6% of patients demonstrate suboptimal responses, with a pathological complete response rate of approximately 10%.Read full original descriptionShow less
Disitamab Vedotin Combined With Cisplatin for Neoadjuvant Therapy in Locally Advanced Cervical Cancer: a Prospective, Single-arm Clinical Trial
In the comprehensive dataset of clinical diagnoses and treatments for cervical cancer in China, 49.8% of patients with stage IB3 and IIA2 receive surgical intervention following neoadjuvant chemotherapy. This indicates a pressing need to optimize neoadjuvant chemotherapy regimens for locally advanced cervical cancer. While paclitaxel combined with cisplatin is the conventional approach, 9.8% to 30.6% of patients demonstrate suboptimal responses, with a pathological complete response rate of approximately 10%.
Currently, the efficacy of antibody-drug conjugates in neoadjuvant chemotherapy for cervical cancer remains unexplored. This study seeks to address this gap by evaluating the combination of Disitamab Vedotin and Cisplatin in patients with stage IB3 and IIA2 cervical cancer with positive HER2 expression.The study will assess the impact of this regimen on pathological complete response rates, surgical complications, surgical resection rates, and overall survival.
Inclusion: Clinical diagnosis of cervical squamous cell carcinoma; HER-2 positive.
Exclusion: Cervical adenocarcinoma.